Rhythm Biosciences (ASX:RHY)
We spoke to Dr David Atkins, CEO of Rhythm Biosciences (ASX:RHY), about the recent completion by Australia’s National Association of Testing Authorities of the ‘variation-to-scope assessment’ for the ColoSTAT blood-based colorectal cancer test.
What this means is that Rhythm is now cleared to offer the test to patients in Australia. Rhythm is now working to expand clinician awareness and referral pathways.
Check out the latest research on RHY by Pitt Street Research!
Looking for the Best ASX Life Sciences stocks to invest in right now?
